3D-bioprinted all-inclusive bioanalytical platforms for cell studies.

Area of Science:

• Biotechnology
• Biomedical Engineering
• Cancer Research

Background:

• Traditional cancer drug screening models (animals, 2D cultures) fail to replicate the human organ microenvironment.
• There is a critical need for advanced platforms that accurately mimic in vivo conditions for effective drug discovery.
• Personalized cancer treatment requires models that recapitulate the complex cellular microenvironment.

Purpose of the Study:

• To develop innovative 3D bioprinting technology for creating organ-on-a-chip-like platforms.
• To engineer high-throughput, customizable platforms for 3D cell analysis and therapeutic response studies.
• To create bio-printed microfluidic systems that mimic physiological conditions for drug screening.

Main Methods:

• Utilized 3D bioprinting to create various geometries of 3D human colon cancer cell constructs.
• Developed and rapidly prototyped polydimethylsiloxane (PDMS)-based microfluidic cell handling arrays.
• Integrated a 3D-bioprinted perfused microfluidic system to simulate physiological fluid flow.

Main Results:

• Successfully fabricated and demonstrated 3D cell constructs in spherical and rectangular shapes.
• Showcased the viability of printed 3D cell constructs for up to seven days.
• Validated the platform's utility by performing cancer cell-therapeutic response studies under perfused conditions.

Conclusions:

• 3D bioprinting enables the creation of sophisticated organ-on-a-chip platforms for advanced cancer research.
• The developed microfluidic systems accurately mimic the human physiological environment for drug screening.
• This technology holds significant potential for improving the discovery of novel and personalized cancer treatments.